Diabetes

Insulin Pump Therapy for Type 1 Diabetes - Tandem®

The pump that gets updated, not outdated.

t:slim X2™ Insulin Pump with Control-IQ™ or Basal-IQ™ Technology 

Whether using Control-IQ or Basal-IQ technology software, the t:slim X2 Insulin Pump has the same pump hardware which offers a slim and sleek design, that is packed with big features such as: 

  • Updatable platform – Capable of remote feature updates^
  • Rechargeable battery – Convenient and easy to charge so there is no need to worry about purchasing extra batteries
  • Large colour touchscreen – Easy-to-read, easy-to-use interface
  • Watertight construction – Tested up to a depth of 1 metre for 30 minutes (IPX7)
  • CGM integration – Compatible with Dexcom G6 Continuous Glucose Monitoring (CGM), which is indicated for making treatment decisions with zero fingerpicks and no calibrations*

*If your glucose alerts and readings from Dexcom G6 do not match symptoms or expectations, use a blood glucose meter to make diabetes treatment decisions.

Control-IQ™ Technology 

When used with the Control-IQ technology software update, the t:slim X2 insulin pump becomes an advanced hybrid closed-loop technology system that keeps your glucose levels in range (that is, 3.9 – 10.0 mmol/L) by predicting and helping prevent both high and low glucose events1, based on readings from Dexcom G6 CGM.

New features like automatic insulin adjustments, automatic correction boluses and Exercise and Sleep Activity settings provide tighter target ranges and more automatic glucose control wherever you are, whatever you’re doing.

Basal-IQ™ Technology 

With Basal-IQ technology installed on the t:slim X2 insulin pump, the software uses CGM readings from Dexcom G6 to help reduce the frequency and duration of low-glucose events2 by predicting glucose levels 30 minutes ahead and suspending insulin if they are expected to drop below 4.4 mmol/L, or if a CGM reading falls below 3.9 mmol/L.

Visit www.amsldiabetes.com.au for full product information.

ALWAYS READ THE LABEL AND FOLLOW THE DIRECTIONS FOR USE. Read the warnings available on amsldiabetes.com.au/resources before purchasing. Consult your healthcare professional to see which product is right for you.

^ Additional feature updates are subject to future regulatory approvals. Charges may apply. Updates only available for insulin pumps within warranty.

 Dexcom G6 CGM sold separately.

¶ Basal-IQ technology is not a substitute for active self-management of your diabetes.


1. Brown SA, Kovatchev BP, Raghinaru D, et al. Six-month randomized, multicenter trial of closed-loop control in type 1 diabetes. N Engl J Med. 2019;381(18):1707-1717.

2. Forlenza GP, Li Z, Buckingham BA, Pinsker JE, et al. Predictive low-glucose suspend reduces hypoglycaemia in adults, adolescents, and children with type 1 diabetes in an at-home randomized crossover study: Results of the PROLOG trial. Diabetes Care. 2018;41(10):2155-2161. doi:10.2337/dc18-0771.

© 2022 Tandem Diabetes Care, Inc. All rights reserved. Tandem Diabetes Care, Control-IQ, Basal-IQ, Micro-delivery, touch simplicity, t:slim X2, and t:simulator are registered trademarks or trademarks of Tandem Diabetes Care, Inc., in the United States and other countries. Dexcom and Dexcom G6 are registered trademarks of Dexcom, Inc. in the United States and/or other countries.